Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just ...

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences: ...

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 results on Nov. 2, 2026. The Zacks Consensus Estimate is pegged at a loss of 24 ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest ...

Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...

Allison covered what hot startups are getting up to, and who’s financing them. She was also co-host of the weekly biotech podcast, “The Readout Loud.” Recursion Pharmaceuticals announced results of a ...

The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...